Liquid biopsy

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, March 5, 2024

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.
  • SOPHiA GENETICS will host a conference call and live webcast to discuss the fourth quarter and full year 2023 results, and financial guidance for the full year 2024 on Tuesday, March 5, 2024, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time.
  • Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.
  • These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans.

Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees

Retrieved on: 
Tuesday, February 20, 2024

Today, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant , recognizing research from the Melanoma Institute Australia, the University of Turin in Italy and Atrium Health Wake Forest Baptist Medical Center.

Key Points: 
  • Today, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant , recognizing research from the Melanoma Institute Australia, the University of Turin in Italy and Atrium Health Wake Forest Baptist Medical Center.
  • Since its introduction in 2020, the Oncomine Clinical Research Grant program has provided up to $200,000 in reagents and general funding for 22 unique research projects conducted by independent clinical research teams.
  • “The Oncomine Clinical Research Grant program provides us the opportunity to support emerging research projects and their goal of delivering on the promise of precision oncology through the democratization of NGS technology,” said Jose Luis Costa, Ph.D., global director, scientific affairs, clinical next-generation sequencing and oncology, Thermo Fisher Scientific.
  • In late 2023, Oncomine Clinical Research Grant recipients had the opportunity to attend a closed Oncomine Scientific Gala to share their research with the wider pharmaceutical community and showcase the results of their studies and the impact NGS testing can have on oncology research and patient care.

Mako Alliance Welcomes Circulogene and Expands Membership Across Five States

Retrieved on: 
Tuesday, March 5, 2024

Circulogene, known for its cutting-edge approach to liquid biopsy testing, provides comprehensive genomic profiling that aids in the detection and monitoring of cancer.

Key Points: 
  • Circulogene, known for its cutting-edge approach to liquid biopsy testing, provides comprehensive genomic profiling that aids in the detection and monitoring of cancer.
  • In addition to welcoming Circulogene, the Mako Alliance is proud to announce the expansion of its network with new members from Texas, Kentucky, Florida, New York, and California.
  • "The integration of Circulogene into the Mako Alliance marks a pivotal moment in our journey to revolutionize patient care through innovation," said a spokesperson for the Mako Alliance .
  • For more information about the Mako Alliance and its members, please visit our website.

BioIVT Announces Expansive Fresh Leukopak Capability in Europe

Retrieved on: 
Thursday, February 22, 2024

WESTBURY, N.Y., Feb. 22, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks. Building on decades of human derived cell collection expertise, this additional capability enables BioIVT to further scale its world-class network of diverse, highly characterized donors and makes the company a leading provider of fresh leukopaks in the UK and mainland Europe.

Key Points: 
  • WESTBURY, N.Y., Feb. 22, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks.
  • Building on decades of human derived cell collection expertise, this additional capability enables BioIVT to further scale its world-class network of diverse, highly characterized donors and makes the company a leading provider of fresh leukopaks in the UK and mainland Europe.
  • To support this growing demand, BioIVT now has the ability to provide researchers across Europe with high quality, fresh starting material within 24 hours of collection.
  • "Access to fresh leukopaks enables clients with the crucial elements needed for effective and efficient therapeutic development and approval," said Dr. Parijat Jain, Vice President, CGT at BioIVT.

nRichDX to Debut New Products & Present Latest Research at AACR 2024 Annual Meeting this April

Retrieved on: 
Tuesday, February 20, 2024

SAN DIEGO, Feb. 20, 2024 /PRNewswire/ -- nRichDX®, best known for the development of its Revolution Sample Prep System™, will be introducing new products, presenting new data, and exhibiting at the American Association for Cancer Research (AACR) 2024 Annual Meeting. Held April 5-10 at the San Diego Convention Center, the conference is dedicated to exploring and recognizing the latest discoveries in cancer research. nRichDX will exhibit in booth #3721, just inside the main registration entrance, and co-present three posters on April 8 & 9. Exhibits open at 1 PM on Sunday April 7 and close at 12:30 PM on Wednesday April 10.

Key Points: 
  • nRichDX will exhibit in booth #3721 , just inside the main registration entrance, and co-present three posters on April 8 & 9.
  • "nRichDX is proud to introduce the next generation of Revolution Sample Prep Instruments and Kits at this year's AACR Annual Meeting."
  • To meet with nRichDX people at AACR 2024 or schedule an in-booth demo, attendees are encouraged to schedule an appointment .
  • To find the latest information about nRichDX's schedule at AACR 2024, please visit nrichdx.com/aacr2024 .

DiaCarta's RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage

Retrieved on: 
Tuesday, February 20, 2024

This innovative approach enables physicians to assess tumor response in real-time, providing critical insights into treatment efficacy.

Key Points: 
  • This innovative approach enables physicians to assess tumor response in real-time, providing critical insights into treatment efficacy.
  • Unlike traditional molecular residual disease (MRD) monitoring, which focuses on specific tumor mutant clones post-treatment, RadTox™ offers a broader perspective.
  • "RadTox™ fills a crucial gap by offering a personalized biomarker that correlates with cell death, providing timely insights into patients' response to tumor treatments."
  • "Our initial findings across 22 tumor types with over 250,000 samples performed globally demonstrates the immense potential of this pan-cancer monitoring test."

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Thursday, February 15, 2024

LOS ANGELES and AMSTERDAM, Feb. 15, 2024 (GLOBE NEWSWIRE) -- GEDiCube (moving forward RenovaroCube), a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • The focus is on early cancer- and early recurrence detection, prediction of response to therapy, and personalized treatment, all via liquid biopsy tests.

Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection

Retrieved on: 
Thursday, February 15, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2024 /PRNewswire/ -- Freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and existing investors. The funding enables Freenome to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform.

Key Points: 
  • The funding enables Freenome to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform.
  • Together, we share a commitment to addressing the pressing need for better cancer screening solutions as we drive to make early cancer detection more convenient, accessible and actionable for everyone," said Mike Nolan, chief executive officer of Freenome.
  • "With this financing, we are well positioned to realize the full potential of our platform in delivering tests for early cancer detection."
  • Enabling wider access to early cancer screening means helping patients receive timely information that can lead to better outcomes.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Tuesday, February 13, 2024

LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • I consider that to be a significant step towards bringing early detection of cancer to its inflection point.”

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test.
  • The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.